Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial

Overview of attention for article published in Alzheimer's Research & Therapy, February 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#41 of 1,484)
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 21 news outlets
blogs: 1 blog

twitter: 14 X users

Citations

dimensions_citation: 22 Dimensions

Readers on

mendeley: 50 Mendeley

Summary News Blogs X Dimensions citations

So far, Altmetric has seen 1 blog post.

A Tyrosine Kinase Inhibitor Produces Improvement in Early Stage Alzheimer's Patients

Fight Aging!, 16 Mar 2023

Senolytic drugs are those that selectively force senescent cells into programmed cell death. Senescent cells accumulate with…

This page shows the most recent blog posts that mention this research output.

Click here to find out how to access more activity.